EPPK1

Summary

EPPK1 (epiplakin 1, HGNC:15577) is a protein-coding gene on chromosome 8q24.3, encoding Epiplakin (P58107). Cytoskeletal linker protein that connects to intermediate filaments and controls their reorganization in response to stress.

The protein encoded by this gene belongs to the plakin family of proteins, which play a role in the organization of cytoskeletal architecture. This family member is composed of several highly homologous plakin repeats. It may function to maintain the integrity of keratin intermediate filament networks in epithelial cells. Studies of the orthologous mouse protein suggest that it accelerates keratinocyte migration during wound healing.

Source: NCBI Gene 83481 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 594 total
• MANE Select transcript: NM_031308

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:15577
Approved symbol	EPPK1
Name	epiplakin 1
Location	8q24.3
Locus type	gene with protein product
Status	Approved
Aliases	EPIPL1
Ensembl gene	ENSG00000261150
Ensembl biotype	protein_coding
OMIM	607553
Entrez	83481

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000568225, ENST00000615648

RefSeq mRNA: 1 — MANE Select: NM_031308 NM_031308

CCDS: CCDS75800

Canonical transcript exons

ENST00000615648 — 2 exons

Exon	Start	End
ENSE00003714145	143857324	143873298
ENSE00003746135	143878438	143878467

Expression profiles

Bgee: expression breadth ubiquitous, 190 present calls, max score 99.04.

FANTOM5 (CAGE): breadth broad, TPM avg 6.0841 / max 285.7633, expressed in 618 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
95547	6.0841	618

Top tissues by expression

271 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skin of hip	UBERON:0001554	99.04	gold quality
upper leg skin	UBERON:0004262	98.53	gold quality
gingival epithelium	UBERON:0001949	98.36	gold quality
gingiva	UBERON:0001828	97.27	gold quality
epithelium of nasopharynx	UBERON:0001951	97.11	gold quality
cauda epididymis	UBERON:0004360	96.23	gold quality
germinal epithelium of ovary	UBERON:0001304	96.10	gold quality
nipple	UBERON:0002030	95.38	gold quality
buccal mucosa cell	CL:0002336	94.66	gold quality
bronchial epithelial cell	CL:0002328	91.99	gold quality
mucosa of sigmoid colon	UBERON:0004993	91.34	gold quality
mammary duct	UBERON:0001765	90.71	gold quality
colonic mucosa	UBERON:0000317	90.36	gold quality
palpebral conjunctiva	UBERON:0001812	89.94	gold quality
jejunal mucosa	UBERON:0000399	89.01	gold quality
epithelium of bronchus	UBERON:0002031	88.46	gold quality
bronchus	UBERON:0002185	88.05	gold quality
parotid gland	UBERON:0001831	87.98	gold quality
mammalian vulva	UBERON:0000997	87.88	gold quality
pharyngeal mucosa	UBERON:0000355	87.71	gold quality
epithelium of mammary gland	UBERON:0003244	87.08	gold quality
ileal mucosa	UBERON:0000331	85.86	silver quality
upper arm skin	UBERON:0004263	85.80	gold quality
saphenous vein	UBERON:0007318	84.64	gold quality
esophagus squamous epithelium	UBERON:0006920	83.41	gold quality
penis	UBERON:0000989	82.91	gold quality
seminal vesicle	UBERON:0000998	82.72	gold quality
epithelium of esophagus	UBERON:0001976	81.22	gold quality
squamous epithelium	UBERON:0006914	80.93	gold quality
zone of skin	UBERON:0000014	80.85	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-GEOD-75367	yes	53.78
E-ANND-3	yes	10.05
E-MTAB-9801	yes	8.54

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

48 targeting EPPK1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-329-3P	99.91	66.56	1234
HSA-MIR-362-3P	99.91	66.38	1267
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-10395-5P	99.86	67.35	676
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-6079	99.84	68.54	1170
HSA-MIR-205-5P	99.81	70.05	1557
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-4743-3P	99.62	68.12	2095
HSA-MIR-425-5P	99.59	67.67	900
HSA-MIR-549A-3P	99.54	68.17	825
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-1324	99.46	66.57	1302
HSA-MIR-185-5P	99.35	68.60	2497
HSA-MIR-4644	99.35	69.12	2514
HSA-MIR-3064-5P	99.26	66.13	1497
HSA-MIR-3085-3P	99.26	66.16	1490

Literature-anchored findings (GeneRIF, showing 2)

• Epiplakin may be a cytolinker involved in maintaining the integrity of intermediate filaments networks in simple epithelial cells. (PMID:15671067)
• KLF5-mediated Eppk1 expression promotes cell proliferation in cervical cancer via the p38 signaling pathway. (PMID:33827480)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Eppk1	ENSMUSG00000118671
rattus_norvegicus	Eppk1	ENSRNOG00000068431

Paralogs (36): SYNE2 (ENSG00000054654), SPTB (ENSG00000070182), ACTN1 (ENSG00000072110), ACTN2 (ENSG00000077522), DSP (ENSG00000096696), DRP2 (ENSG00000102385), SPTBN1 (ENSG00000115306), MACF1 (ENSG00000127603), FLNC (ENSG00000128591), ACTN4 (ENSG00000130402), SYNE1 (ENSG00000131018), MICAL2 (ENSG00000133816), DTNA (ENSG00000134769), MICAL1 (ENSG00000135596), FLNB (ENSG00000136068), SPTBN5 (ENSG00000137877), DTNB (ENSG00000138101), GAS2L3 (ENSG00000139354), DST (ENSG00000151914), UTRN (ENSG00000152818), SPTBN4 (ENSG00000160460), SPTA1 (ENSG00000163554), CLMN (ENSG00000165959), PKHD1 (ENSG00000170927), SPTBN2 (ENSG00000173898), SYNE3 (ENSG00000176438), PLEC (ENSG00000178209), SMTNL2 (ENSG00000188176), FLNA (ENSG00000196924), SPTAN1 (ENSG00000197694), DMD (ENSG00000198947), PKHD1L1 (ENSG00000205038), DYTN (ENSG00000232125), MICAL3 (ENSG00000243156), ACTN3 (ENSG00000248746), GAS2L2 (ENSG00000270765)

Protein

Protein identifiers

Epiplakin — P58107 (reviewed: P58107)

Alternative names: 450 kDa epidermal antigen

All UniProt accessions (2): A0A075B730, P58107

UniProt curated annotations — full annotation on UniProt →

Function. Cytoskeletal linker protein that connects to intermediate filaments and controls their reorganization in response to stress. In response to mechanical stress like wound healing, is associated with the machinery for cellular motility by slowing down keratinocyte migration and proliferation and accelerating keratin bundling in proliferating keratinocytes thus contributing to tissue architecture. However in wound healing in corneal epithelium also positively regulates cell differentiation and proliferation and negatively regulates migration thereby controlling corneal epithelium morphogenesis and integrity. In response to cellular stress, plays a role in keratin filament reorganization, probably by protecting keratin filaments against disruption. During liver and pancreas injuries, plays a protective role by chaperoning disease-induced intermediate filament reorganization.

Subunit / interactions. Interacts with KRT5, KRT14 and KRT5/KRT14 heterotetramer; interacts preferentially with assembled filaments rather than keratin monomers. Interacts with KRT8 and KRT18 and KRT8/KRT18 heterotetramer; interacts preferentially with assembled filaments rather than keratin monomers. Interacts with KRT1, VIM and DES; interaction is stronger with KRT1 than with VIM or DES; interaction is dependent of higher-order structure of intermediate filament.

Subcellular location. Cytoplasm. Cytoskeleton. Cell junction. Hemidesmosome. Tight junction. Cell projection. Apicolateral cell membrane. Basolateral cell membrane.

Tissue specificity. Expressed in epithelial cells of liver, small intestine, colon, salivary glands, stomach and appendix.

Domain organisation. Plectin repeats are important for the binding to keratin and VIM and controls intermediate filament networks organization.

Induction. Up-regulated upon calcium-mediated keratinocyte differentiation.

Similarity. Belongs to the plakin or cytolinker family.

RefSeq proteins (1): NP_112598* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001101	Plectin_repeat	Repeat
IPR035915	Plakin_repeat_sf	Homologous_superfamily
IPR043197	Plakin	Family

Pfam: PF00681

UniProt features (139 total): repeat 65, sequence conflict 36, modified residue 17, region of interest 9, compositionally biased region 8, coiled-coil region 2, chain 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

No AlphaFold model available for P58107 — AlphaFold DB does not currently provide models for proteins above ~3000 aa.

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (17): 4645, 4850, 34, 1543, 2422, 2508, 2718, 2958, 3044, 3249, 3489, 3575, 3783, 4023, 4109, 4317, 4557

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 161 (showing top): GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_CELL_PROLIFERATION, SHEPARD_BMYB_MORPHOLINO_UP, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_INTERMEDIATE_FILAMENT_BASED_PROCESS, GOBP_REGULATION_OF_WOUND_HEALING, GOBP_INTERMEDIATE_FILAMENT_ORGANIZATION, JAEGER_METASTASIS_DN, GOBP_REGULATION_OF_DEVELOPMENTAL_GROWTH, PEREZ_TP63_TARGETS, GOBP_KERATINOCYTE_PROLIFERATION, GOBP_REGULATION_OF_EPITHELIAL_CELL_MIGRATION, GOBP_GROWTH, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_DN, GOBP_REGENERATION, NAGASHIMA_NRG1_SIGNALING_UP

GO Biological Process (10): negative regulation of keratinocyte proliferation (GO:0010839), negative regulation of cell migration (GO:0030336), wound healing (GO:0042060), intermediate filament organization (GO:0045109), intermediate filament bundle assembly (GO:0045110), negative regulation of epithelial cell proliferation (GO:0050680), negative regulation of keratinocyte migration (GO:0051548), negative regulation of wound healing (GO:0061045), regulation of epithelium regeneration (GO:1905041), intermediate filament cytoskeleton organization (GO:0045104)

GO Molecular Function (4): RNA binding (GO:0003723), structural molecule activity (GO:0005198), intermediate filament binding (GO:0019215), keratin filament binding (GO:1990254)

GO Cellular Component (17): cytoplasm (GO:0005737), cytoskeleton (GO:0005856), bicellular tight junction (GO:0005923), membrane (GO:0016020), basolateral plasma membrane (GO:0016323), apicolateral plasma membrane (GO:0016327), cell junction (GO:0030054), hemidesmosome (GO:0030056), cell projection (GO:0042995), keratin filament (GO:0045095), intermediate filament cytoskeleton (GO:0045111), cell periphery (GO:0071944), perinucleolar compartment (GO:0097356), intermediate filament (GO:0005882), plasma membrane (GO:0005886), cell-cell junction (GO:0005911), anchoring junction (GO:0070161)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	6
plasma membrane region	2
regulation of keratinocyte proliferation	1
keratinocyte proliferation	1
negative regulation of epithelial cell proliferation	1
cell migration	1
regulation of cell migration	1
negative regulation of cell motility	1
response to wounding	1
tissue regeneration	1
intermediate filament cytoskeleton organization	1
supramolecular fiber organization	1
cellular component assembly	1
intermediate filament organization	1
negative regulation of cell population proliferation	1
epithelial cell proliferation	1
regulation of epithelial cell proliferation	1
negative regulation of epithelial cell migration	1
keratinocyte migration	1
regulation of keratinocyte migration	1
negative regulation of response to external stimulus	1
wound healing	1
regulation of wound healing	1
negative regulation of response to wounding	1
regulation of developmental growth	1
epithelium regeneration	1
cytoskeleton organization	1
intermediate filament-based process	1
nucleic acid binding	1
molecular_function	1
binding	1
intermediate filament binding	1
intracellular anatomical structure	1
intracellular membraneless organelle	1
apical junction complex	1
tight junction	1
basal plasma membrane	1
cell-substrate junction	1
intermediate filament	1
cytoskeleton	1

Protein interactions and networks

STRING

1260 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
EPPK1	PPL	O60437	668
EPPK1	DST	Q03001	620
EPPK1	A2ML1	A8K2U0	574
EPPK1	MACF1	Q9UPN3	506
EPPK1	DSG3	P32926	505
EPPK1	KRT8	P05787	497
EPPK1	DSG1	Q02413	420
EPPK1	H7BZ11	H7BZ11	411
EPPK1	ANO7	Q6IWH7	410
EPPK1	PKP3	Q9Y446	407
EPPK1	DSP	P15924	396
EPPK1	PKHD1	P08F94	382
EPPK1	NRBP2	Q9NSY0	381
EPPK1	OR8U1	Q8NH10	379
EPPK1	METTL21C	Q5VZV1	373

IntAct

157 interactions, top by confidence:

A	B	Type	Score
GRB2	EGFR	psi-mi:“MI:0914”(association)	0.980
VIM	NEFL	psi-mi:“MI:0914”(association)	0.840
YWHAH	FAM83G	psi-mi:“MI:0914”(association)	0.710
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
ORF	EIF3F	psi-mi:“MI:0914”(association)	0.560
ZSCAN12	A2ML1	psi-mi:“MI:0914”(association)	0.530
TBC1D22B	A2ML1	psi-mi:“MI:0914”(association)	0.530
RBM24	PPL	psi-mi:“MI:0914”(association)	0.530
YWHAQ	IGLC7	psi-mi:“MI:0914”(association)	0.530
NEFM	EVI5	psi-mi:“MI:0914”(association)	0.530
WDR83	SH2B2	psi-mi:“MI:0914”(association)	0.530
CFTR	PLEKHG3	psi-mi:“MI:0914”(association)	0.480

BioGRID (255): EPPK1 (Affinity Capture-MS), EPPK1 (Affinity Capture-MS), EPPK1 (Affinity Capture-MS), EPPK1 (Affinity Capture-MS), EPPK1 (Affinity Capture-MS), EPPK1 (Affinity Capture-MS), EPPK1 (Affinity Capture-MS), EPPK1 (Affinity Capture-MS), EPPK1 (Affinity Capture-MS), EPPK1 (Proximity Label-MS), EPPK1 (Proximity Label-MS), EPPK1 (Proximity Label-MS), EPPK1 (Proximity Label-MS), EPPK1 (Affinity Capture-MS), EPPK1 (Affinity Capture-MS)

ESM2 similar proteins: A0A4X1T4U3, A2SW69, A5A6L7, A6H603, A6NMY6, C1L7Y4, O35640, O76027, O97529, P04272, P07355, P07356, P13928, P14950, P17785, P19620, P21671, P24551, P24801, P27006, P51074, P51901, P58107, P93157, Q07936, Q2Q1M6, Q3ZBE0, Q3ZC08, Q5R5A0, Q5VT79, Q66KB7, Q6NVG1, Q6TEQ7, Q86U10, Q86VI3, Q8MIR4, Q8R0W0, Q8SPR7, Q92040, Q92108

Diamond homologs: A0A8M2BID5, A0A8M9PQ61, D3ZHV2, E9Q557, F1LMV6, P15924, P30427, P58107, Q15149, Q8R0W0, Q92817, Q9D952, Q9JI55, Q9QXS1, O60437, Q9R269, Q03001, Q91ZU6, Q9QXZ0, Q9UPN3, A5D7D1, D3ZHA0, D3ZQL6, E1BBG2, G1T168, G3V7L1, L7UZ85, M9MRD1, O13614, O13728, O14112, O15020, O43707, O75369, O76329, O77082, O77302, O88990, O97592, P05094

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 185 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of the cornified envelope	19	13.7×	7e-14
Keratinization	18	8.2×	2e-09

GO biological processes:

GO term	Partners	Fold	FDR
intermediate filament organization	18	27.2×	3e-18
autophagosome maturation	7	15.5×	1e-04
keratinization	10	14.7×	1e-06
morphogenesis of an epithelium	6	13.0×	2e-03
epithelial cell differentiation	8	8.8×	1e-03
negative regulation of canonical NF-kappaB signal transduction	8	8.7×	1e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

594 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	354
Likely benign	177
Benign	62

Top pathogenic / likely-pathogenic (0)

SpliceAI

520 predictions. Top by Δscore:

Variant	Effect	Δscore
8:143875355:C:A	donor_gain	0.9800
8:143878440:G:A	donor_gain	0.9700
8:143873294:CTGTC:C	acceptor_gain	0.9100
8:143875354:T:TA	donor_gain	0.9100
8:143878432:CCGCA:C	donor_loss	0.9100
8:143878433:CGCA:C	donor_loss	0.9100
8:143878434:GCA:G	donor_loss	0.9100
8:143878435:CA:C	donor_loss	0.9100
8:143878437:CC:C	donor_loss	0.9100
8:143878438:C:G	donor_loss	0.8900
8:143873299:C:T	acceptor_loss	0.8800
8:143873300:T:A	acceptor_loss	0.8800
8:143878394:G:A	donor_gain	0.8800
8:143873301:G:C	acceptor_loss	0.8700
8:143877240:C:A	donor_gain	0.8700
8:143878278:AC:A	donor_gain	0.8600
8:143878279:CC:C	donor_gain	0.8600
8:143873310:A:T	acceptor_loss	0.8400
8:143875350:C:CA	donor_gain	0.8400
8:143875452:CCA:C	donor_gain	0.8400
8:143878430:C:T	donor_gain	0.8200
8:143878431:GCC:G	donor_loss	0.8100
8:143878448:G:A	donor_gain	0.8100
8:143873299:C:CC	acceptor_gain	0.8000
8:143875415:AGAG:A	donor_gain	0.8000
8:143875454:A:AC	donor_gain	0.8000
8:143873319:CAAT:C	acceptor_loss	0.7900
8:143877239:T:TA	donor_gain	0.7900
8:143878375:G:A	donor_gain	0.7900
8:143873309:C:CT	acceptor_loss	0.7600

AlphaMissense

32464 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:143861252:A:G	L4001P	0.999
8:143858237:A:G	L5006P	0.998
8:143861290:G:C	F3988L	0.998
8:143861290:G:T	F3988L	0.998
8:143861292:A:G	F3988L	0.998
8:143861293:G:C	F3987L	0.998
8:143861293:G:T	F3987L	0.998
8:143861295:A:G	F3987L	0.998
8:143862854:A:G	L3467P	0.998
8:143864447:A:G	L2936P	0.998
8:143864488:G:C	F2922L	0.998
8:143864488:G:T	F2922L	0.998
8:143864490:A:G	F2922L	0.998
8:143864633:A:G	L2874P	0.998
8:143864676:C:G	A2860P	0.998
8:143866055:A:G	L2400P	0.998
8:143859950:A:G	L4435P	0.997
8:143861267:A:G	L3996P	0.997
8:143861438:A:G	L3939P	0.997
8:143861552:A:G	L3901P	0.997
8:143861774:A:T	I3827N	0.997
8:143864485:G:C	F2923L	0.997
8:143864485:G:T	F2923L	0.997
8:143864487:A:G	F2923L	0.997
8:143864660:A:G	L2865P	0.997
8:143858351:A:G	L4968P	0.996
8:143858394:C:G	A4954P	0.996
8:143858518:G:C	S4912R	0.996
8:143858518:G:T	S4912R	0.996
8:143858520:T:G	S4912R	0.996

dbSNP variants (sampled 300 via entrez): RS1000620600 (8:143873085 C>T), RS1000734905 (8:143872945 C>G,T), RS1001031141 (8:143866753 G>A,C), RS1001417527 (8:143874866 C>T), RS1001470014 (8:143880139 C>G), RS1001834976 (8:143877929 C>A,T), RS1002475142 (8:143878150 G>A,C), RS1002823214 (8:143874045 C>T), RS1003258674 (8:143857162 A>C), RS1003373146 (8:143856947 C>A,T), RS1003492536 (8:143875880 A>C), RS1003510827 (8:143879981 G>A,T), RS1004039605 (8:143866989 C>T), RS1005051611 (8:143857919 A>C), RS1005214435 (8:143874666 G>T)

Disease associations

OMIM: gene MIM:607553 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): myoepithelial tumor (MONDO:0002380)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST004881_4	Knee osteoarthritis	5.000000e-07
GCST009597_153	Multiple sclerosis	2.000000e-08

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D009208	Myoepithelioma	C04.557.435.585

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

77 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	increases expression, affects cotreatment	3
Valproic Acid	increases expression, increases methylation	3
bisphenol A	decreases expression, increases expression	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression, increases expression	2
Air Pollutants	increases oxidation, increases expression, affects cotreatment, increases abundance	2
Benzo(a)pyrene	increases expression, increases methylation, affects methylation	2
Caffeine	decreases expression, decreases phosphorylation	2
Estradiol	increases expression, affects cotreatment, decreases expression	2
Mustard Gas	increases expression, increases phosphorylation	2
Nickel	increases expression	2
Smoke	decreases expression, increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
Cadmium Chloride	decreases expression, increases expression	2
aristolochic acid I	increases expression	1
sotorasib	affects cotreatment, decreases expression	1
dicrotophos	increases expression	1
methylmercuric chloride	decreases expression	1
alpha-pinene	increases abundance, affects cotreatment, increases oxidation	1
deoxynivalenol	decreases expression	1
titanium dioxide	decreases expression	1
pyrogallol 1,3-dimethyl ether	affects cotreatment, affects localization, decreases expression, increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
mono-(2-ethylhexyl)phthalate	decreases expression	1
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid	increases abundance, affects methylation	1
sodium arsenite	decreases expression	1
benzo(e)pyrene	decreases methylation	1
coumarin	increases phosphorylation	1
methacrylaldehyde	affects cotreatment, increases oxidation, increases abundance	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
epigallocatechin gallate	decreases expression	1

Clinical trials (associated diseases)

5 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03600649	PHASE1	UNKNOWN	Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas
NCT05266196	PHASE1/PHASE2	UNKNOWN	A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)
NCT06239272	PHASE1/PHASE2	RECRUITING	NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
NCT06625190	PHASE1/PHASE2	RECRUITING	Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
NCT06244420	Not specified	COMPLETED	Malignant Myoepithelioma of Bone and Soft Tissues: Diagnostic Imaging and Histology in Relation to Prognosis